CEM Wins Peptide Patent Dispute with Biotage - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

CEM Wins Peptide Patent Dispute with Biotage


CEM Corporation announced in a press release that its European Patent No. 1 491 552 covering microwave assisted solid phase peptide synthesis has been upheld in an oral proceeding at the European Patent Office. The opposition proceeding had been initiated by Biotage in an attempt to revoke the patent.

According to the statement, the patent broadly covers the overall process of microwave peptide synthesis including the steps of deprotection and coupling. Biotage was unable to find or provide any new prior art that could be used to nullify the patent.

“Microwave peptide synthesis using the methods claimed in EP 1 491 552 can only be performed using CEM microwave systems which carry a license for this process,” commented Michael J. Collins, PhD, president and CEO of CEM Corporation. “No other microwave systems (including Biotage) can be offered or used to perform CEM’s patented microwave peptide synthesis (including deprotection and coupling) without being in violation of this or other related CEM patents. Obviously, we will continue to ensure that all of our intellectual property rights are fully enforced and protected.
CEM has similar issued patents in the United States, Canada, and Japan.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
21%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
8%
Regulatory compliance
42%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here